Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT vs Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia
NCT02844361Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2016
- Primary completion
- Nov 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 4 trial of Autologous Mesenchymal Stem Cells in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2016; status: completed.
02
Drugs
Autologous Mesenchymal Stem Cells
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02844361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844361.